by GV Team | Jan 20, 2020 | Drug Information, Messages from CEO, Patient Safety, Resources
Article by American Family Physician, www.aafp.org The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (i.e., at least 65 years of age), originally developed by Mark H. Beers in 1991, continue to be used by the American Geriatrics Society...
by GV Team | Nov 12, 2019 | Drug Information, Messages from CEO, Patient Safety, Resources
Blog by Mark Prifogle, GrandView Pharmacy CEO You may have noticed a new sticker on prescription packaging that states “NIOSH” or hazardous drugs recently. This sticker indicates a revised class of drugs around hazardous waste/medications update from earlier...
by GV Team | Jul 19, 2019 | Drug Information, Messages from CEO, Patient Safety, Resources
Update from the Centers for Disease Control and Prevention Tuberculin Skin Test – Aplisol Shortage The Centers for Disease Control and Prevention (CDC) is expecting a 3–10 month nationwide shortage of Aplisol. Aplisol is one of two purified-protein derivative (PPD)...
by GV Team | Mar 8, 2019 | Messages from CEO, Resources
Blog by Mark Prifogle, GrandView Pharmacy CEO We’re excited to announce upcoming education events! LeadingAge Indiana, in partnership with Samaritan Alliance, has put together opportunities to Lunch and Learn together! Topic: Value Based Purchasing Lunch &...
by GV Team | Nov 8, 2018 | GrandView News, Messages from CEO, Patient Safety, Resources
Blog by Mark Prifogle, GrandView Pharmacy CEO I am happy to announce two recent changes, as it relates to our infusion service program for skilled nursing communities. While we have continued to support the Baxter 6201 model, it was discovered recently, we cannot get...
by GV Team | Aug 28, 2018 | Messages from CEO, Patient Safety, Regulation Changes, Resources
Blog by Mark Prifogle, GrandView Pharmacy CEO I have shared these documents with our team to help them better understand how our customers and skilled nursing facilities get reimbursed in Indiana. As a group, we must focus on how to use the best evidence-based...
